RemeGen is a biopharmaceutical company with integrated capabilities in research, discovery, clinical development, manufacturing and commercialization of biologic drugs. Founded in 2008 and led by CEO Jianmin Fang, the company focuses on innovative biologics for autoimmune diseases, cancer, and ophthalmology. It has built a pipeline of over 10 innovative molecules, with two molecules spanning five indications currently in Phase III or pivotal trials in China, and one new drug application filed. Its lead molecules are RC18 (telitacicept), a fusion protein with an NDA filed in China for systemic lupus erythematosus and additional Phase II/III programs across six autoimmune indications, and RC48, a HER2 antibody‑drug conjugate in pivotal trials for gastric and urothelial cancers. RemeGen intends to use funds to continue developing its early‑stage drug discovery platform, expand manufacturing facilities, and advance commercialization of RC18 and RC48. The company recently closed an approximately $100M private financing round to support those efforts.

Total raised

$100M

Funding rounds

1

Latest round

Equity

Latest activity

Apr 2020